atDose was Founded on September 1, 2017 in Yokohama City, Kanagawa, Japan. Here's our logo at the time of our founding.
2017.9.1The CEO of atDose was selected as one of the 20 members of "Sido Next Innovator 2017" sponsored by the Ministry of Economy, Trade and Industry in Silicon Valley.
2018.1.22-2.4Just one year after the company's launch, we set up a development base at the KBIC incubation facility in Kawasaki City.
2018.9.1CEO was granted to the "Research and Development Venture Support Project" by NEDO. NEDO is a national research and development agency that creates innovation by promoting technological development necessary for realization of a sustainable society.
2019.1.18The project has been selected for the "Research to Promote Industry-Academia-Government Collaboration" by the Kanagawa Institute of Science and Technology (KISTEC), a local independent administrative agency.
2019.6.12atDose has been selected as one of the four companies to be supported by the City of Yokohama's "The Springboard™ Program in Yokohama".
2019.7.4We were selected as one of eight companies in the Yokohama Acceleration Program, which supports the growth and development of venture businesses.
2019.7.25atDose was selected as one of the 12 finalist teams for the TECH PLANTER Biotech Grand Prix and received the Corporate Award "Mitsui Chemicals Award" at the final round.
2019.9.21atDose Co., Ltd. , Phenovance Research & Technology, LLC and Teslasheet Inc. have signed a joint research agreement starting October 10, 2019.
2019.10.10atDose was selected as one of the 12 companies in the YOXO Accelerator Program of Yokohama City.
2019.12.26At the Yokohama Business Grand Prix, held in Yokohama Minato Mirai, we received the Audience Award, which was decided by the audience's vote.
2020.2.22atDose and our mobile drip device were featured on TV Tokyo and BS Tele-to "Change the World - Vision to Build the Future".
2020.3.29We obtained a license for the manufacture and sale of medical devices from Kanagawa Prefecture. Type of License: Class 1 Medical Device Marketing Authorization (All three medical device classifications can be handled) MAH No. 14B1X10026
2020.7.22We have begun development of the atDose Multi, a miniaturized syringe pump used for intravenous (IV) medication. We will continue to develop three products: Core, Mobile, and Multi.
2020.8.6DEFTA Healthcare Technologies, L.P. (based in the U.S., Israel, Japan, Hong Kong, etc. / GP: DEFTA Capital, Inc. etc.; hereinafter referred to as "DHCT") and private investors raised 55.5 million yen through a private placement of new shares.
2020.8.31atDose and Think-Land will enter into a joint research agreement from September 2, 2020, to solve the challenges of the beauty industry.
2020.9.2The logo was redesigned and the website was updated.
2020.10.28DEFTA Healthcare Technologies, L.P. (based in the U.S., Israel, Japan, Hong Kong, etc. / GP: DEFTA Capital, Inc. etc.; hereinafter referred to as "DHCT") raised 40 million yen through a private placement of new shares.
2021.8.31JETRO will host an online acceleration program in partnership with the Cabinet Office of Japan from October 2021 to March 2022. In this program, JETRO will collaborate with 6 major accelerators to cultivate the growth of Japanese startup ecosystems. We have been selected as one of the 10 companies for the Bio/Healthcare Course by CIC.
2021.11.04We received the Kanagawa Prefecture Governor's Award at the final judging of the Kanagawa Business Audition 2022, a business contest having a long history with 26 years.
2022.1.25